Experimental Biology and Medicine · 2006 · 84 citations · 44 references
Life SciencesImmunologyOncologyApoptosisCarcinogenesisNeoplasiaApoptosis In CancerChemical CarcinogenesisMalignant NeoplasmsT Cell BiologyCarcinogenic Hepatic EffectsFos OncogenesOrgan-specific CarcinogenesisTumor Cell ProliferationWestern Blotting
There is an increasing amount of evidence suggesting that T cell deficiency contributes to tumor development. However, it is unclear whether T cell deficiency leads to liver and colon carcinogenesis. The aim of this study was to investigate the role of T cells on liver and colon carcinogenesis. Athymic F344/N Jcl-rnu/- (nu/nu) rats and euthymic F344/N Jcl-rnu/+(nu/+) rats were administered the carcinogen azoxymethane (AOM) at a dose of 15 mg/kg body wt once a week for 2 weeks. At 48 weeks after the second carcinogen treatment, the rats were sacrificed, and livers and colons were examined. Apoptosis and cell proliferation were evaluated by DNA fragmentation and proliferating cell nuclear antigen assays, respectively. Wild-type p53 and members of the Jun and Fos oncogene families were detected by Western blotting. AOM treatment induced 100% liver tumor and 63.6% colon tumor incidence in T cell-deficient nu/nu rats, compared with 0% and 38.5% incidence in nu/+ rats. T cell deficiency promoted the inhibitory action of AOM on apoptosis in both liver and colon at 48 weeks. In contrast, T cell deficiency increased cell proliferation after AOM treatment in both tissues. Wild-type p53 was reduced in both tissues of T cell-deficient rats. AOM treatment induced c-Jun and c-Fos expressions in the liver but increased only Fos B in the colon, whereas T cell deficiency enhanced c-Jun overexpression in the liver. These results suggest that T cell deficiency leads to liver carcinogenesis partly by a reduction in wild-type p53 and increasing c-Jun expression in AOM-treated rats.
44
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Mark E. Dudley, John R. Wunderlich, Paul F. Robbins et al. · Science · 2002 · 2.8K citations · Full text
Life Sciences, Immunology, Oncology +17
Definition of a consensus binding site for p53
Wafik S. El‐Deiry, Scott E. Kern, Jennifer A. Pietenpol et al. · Nature Genetics · 1992 · 2K citations
Current Protocols in Molecular Biology
Raymond L. Teplitz · JAMA · 1989 · 1.9K citations
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Veronika Groh, Jennifer D. Wu, Cassian Yee et al. · Nature · 2002 · 1.6K citations
Life Sciences, Immunology, Oncology +15
The Central Role of CD4+ T Cells in the Antitumor Immune Response
Kenneth E. Hung, Robert J. Hayashi, Anne Lafond-Walker et al. · The Journal of Experimental Medicine · 1998 · 1.3K citations · Full text
Life Sciences, Immunology, Oncology +17